Safety profile of soft gelatin formulation of saquinavir in combination with nucleosides in a broad patient population. NV15182 Study Team.
M J
MJ
Gill
D019380:Anti-HIV Agents / Q000009:adverse effects* / Q000627:therapeutic use; D002214:Capsules; D002626:Chemistry, Pharmaceutical; D004359:Drug Therapy, Combination; D005780:Gelatin; D015658:HIV Infections / Q000188:drug therapy* / Q000276:immunology / Q000821:virology; D017320:HIV Protease Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use; D006801:Humans; D009705:Nucleosides / Q000627:therapeutic use; D019258:Saquinavir / Q000009:adverse effects* / Q000627:therapeutic use
D019380:Anti-HIV Agents; D002214:Capsules; D017320:HIV Protease Inhibitors; D009705:Nucleosides; D005780:Gelatin; D019258:Saquinavir